港股概念追踪 | 首个国产新冠中和抗体药物商业放行 新冠治疗仍是全年确定性机会(附概念股)

智通财经2022-07-07

智通财经APP获悉,7月7日,腾盛博药-B(02137)及其旗下控股公司腾盛华创宣布,其长效新冠中和抗体安巴韦单抗和罗米司韦单抗联合疗法在中国商业化上市。7月7日,首批抗体药物实现商业放行,标志着这一联合疗法正式开启商业化的重要里程碑。受此消息影响,今日港股腾盛博药-B(02137)最高涨30.24%。中航证券认为,近期新冠口服药研发进展和相关产业链供应的陆续披露,为新冠治疗产业链带来确定性较强的...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
1